<DOC>
	<DOCNO>NCT02983851</DOCNO>
	<brief_summary>VENIM multicenter , open-label , parallel-group randomize control trial study initial ventilation strategy adult immunocompromised patient acute respiratory failure .</brief_summary>
	<brief_title>Initial Ventilation Strategy Adult Immunocompromised Patients With Acute Respiratory Failure</brief_title>
	<detailed_description>The VENIM multicenter randomize control trial ( RCT ) compare effect NIV compare IMV adult immunocompromised patient moderate severe acute respiratory failure ( ARF ) . Patients meet indication ventilatory support include . The intervention consist randomly allocation , treatment NIV IMV , concomitant medication . Primary outcome 30-day hospital mortality . Secondary outcome include in-hospital mortality , length stay hospital , improvement oxygenation , nosocomial infection , seven-day organ failure , adverse event intervention , et al . Subgroups different disease severity , cause immunodeficiency type ARF also analyze .</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<criteria>Adult ( 18 year old ≤ age ≤ 80 year old ) immunocompromised patient admitted hospital moderate severe ARF diagnose within last 72 hour , meet indications ventilatory support . Patients consider moderate severe ARF ratio partial pressure arterial oxygen fraction inspire oxygen ( PaO2/FiO2 ) 85 170 patient breathe oxygen Venturi mask , clinically diagnose follow : 1 . 30 mmHg &lt; PaO2 &lt; 50 mmHg room air ; 2 . Clinical evidence respiratory distress ( intercostal recession , polypnea &gt; 35/min dyspnea rest ) . Patients consider immunocompromised clinically diagnose least one following : 1 . HIV infection ; 2 . Hematologic malignancy solid tumor chemotherapy ; 3 . Solid organ stem cell transplant ; 4 . Longterm ( &gt; 30 day ) high dose steroid ( &gt; 1 mg/kg/d prednisone equivalent ) usage and/or immunosuppressive drug ; 5 . Neutropenia ( define neutrocyte count &lt; 0.50×109/L ) show least 48 hour Age &lt; 18 &gt; 80 year old ; Partial pressure arterial carbon dioxide ( PaCO2 ) &gt; 50 mmHg arterial pH &lt; 7.20 ; PaO2/FiO2 &gt; 170 PaO2/FiO2 &lt; 85 ; Patients treat NIV IMV within 30 day . NIV contraindicate IMV definitely indicate , include PaO2/FiO2 &lt; 85 , respiratory arrest , hemodynamic instability , inability fit face mask , pneumothorax , vomit , development airway bleeding , inability protect airway , copious respiratory secretion ; Comorbided severe disease , include New York Heart Association functional class ≥ II , valvular heart disease , dilate cardiomyopathy , cardiogenic pulmonary edema , implanted cardiac pacemaker , unstable angina , myocardial infarction , cardiac surgery within previous 3 month ; systolic arterial pressure &lt; 90 mmHg optimal fluid therapy ; history chronic obstructive pulmonary disease ( COPD ) asthma ; impaired consciousness ( Glasgow Coma Scale score &lt; 13 ) ; postoperative acute respiratory failure ; pregnancy breastfeeding ; Lack consent , donotintubate decision , situation obvious bias expect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Noninvasive mechanical ventilation</keyword>
	<keyword>Invasive mechanical ventilation</keyword>
</DOC>